Short Interest in bioAffinity Technologies, Inc. (NASDAQ:BIAF) Declines By 37.4%

Posted by Francis Steltz on Aug 18th, 2026

bioAffinity Technologies, Inc. (NASDAQ:BIAF – Get Free Report) saw a significant decrease in short interest in July. As of July 31st, there was short interest totaling 327,035 shares, a decrease of 37.4% from the July 15th total of 522,561 shares. Based on an average trading volume of 217,393 shares, the short-interest ratio is presently 1.5 days. Approximately 7.1% of the company’s shares are short sold.

Analyst Ratings Changes

A number of brokerages recently weighed in on BIAF. Wall Street Zen raised shares of bioAffinity Technologies from a “sell” rating to a “hold” rating in a research report on Monday, August 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of bioAffinity Technologies in a research note on Monday, July 20th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Get Our Latest Stock Report on BIAF

bioAffinity Technologies Stock Up 22.4%

Shares of NASDAQ BIAF traded up $0.09 during trading on Tuesday, reaching $0.48. 163,175,776 shares of the stock were exchanged, compared to its average volume of 4,677,374. The business’s 50-day moving average price is $0.77 and its 200 day moving average price is $1.61. bioAffinity Technologies has a twelve month low of $0.33 and a twelve month high of $13.50. The company has a quick ratio of 1.41, a current ratio of 1.44 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $3.89 million, a price-to-earnings ratio of -0.07 and a beta of -1.04.

bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) last announced its earnings results on Friday, August 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.10) by $1.46. bioAffinity Technologies had a negative return on equity of 220.52% and a negative net margin of 257.30%.The business had revenue of $1.51 million for the quarter, compared to analyst estimates of $1.70 million.

Institutional Investors Weigh In On bioAffinity Technologies

Several hedge funds and other institutional investors have recently bought and sold shares of BIAF. Scientech Research LLC purchased a new stake in bioAffinity Technologies during the 3rd quarter worth approximately $49,000. Geode Capital Management LLC purchased a new position in shares of bioAffinity Technologies during the 4th quarter valued at approximately $36,000. Finally, J. Safra Sarasin Holding AG acquired a new stake in shares of bioAffinity Technologies during the first quarter worth approximately $164,000. 1.64% of the stock is currently owned by hedge funds and other institutional investors.

bioAffinity Technologies Company Profile

(Get Free Report)

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.